We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY2484595 on the Electrical Activity of the Heart

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01537887
Recruitment Status : Completed
First Posted : February 23, 2012
Last Update Posted : June 27, 2012
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to evaluate the effect on the electrical activity of the heart as measured by an electrocardiogram (ECG) after dosing with 10 days of LY2484595 compared to 10 days of placebo in relation to a single dose of moxifloxacin. Information about any side effects that occur will also be collected.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: LY2484595 Drug: Placebo Drug: Moxifloxacin Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects
Study Start Date : February 2012
Primary Completion Date : June 2012
Study Completion Date : June 2012

Arm Intervention/treatment
Placebo Comparator: Placebo
Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14 day washout period.
Drug: Placebo
Administered orally once daily for 10 days.
Experimental: 1200 mg LY2484595
Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14 day washout period.
Drug: LY2484595
Administered orally once daily for 10 days.
Active Comparator: 400 mg Moxifloxacin
Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14 day washout period.
Drug: Moxifloxacin
Single dose administered orally.



Primary Outcome Measures :
  1. Change from baseline in QT interval corrected for heart rate (QTc) for LY2484595 versus placebo [ Time Frame: Baseline, Day 10 ]

Secondary Outcome Measures :
  1. Pharmacokinetics: maximum drug concentration (Cmax) of LY2484595 [ Time Frame: Baseline through Day 15 ]
  2. Pharmacokinetics: area under the concentration curve (AUC) of LY2484595 [ Time Frame: Baseline through Day 15 ]
  3. Change from baseline to Day 15 in fasting lipid and apolipoprotein profiles [ Time Frame: Baseline, Day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males and females
  • Body mass index (BMI) of 18.5 to 29 kg/m^2
  • Reliable and willing to be available for the duration of the study and are willing to follow study procedures
  • Provided written informed consent

Exclusion Criteria:

  • Known allergies to LY2484595 or moxifloxacin
  • Personal or family history of long QT syndrome, heart failure, or low blood potassium (hypokalemia) a family history of sudden death, or unexplained syncope within the last year
  • Positive findings on urinary drug screening
  • Cigarette smokers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01537887


Locations
United States, Florida
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Daytona Beach, Florida, United States, 32117
United States, Indiana
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01537887     History of Changes
Other Study ID Numbers: 11947
I1V-MC-EIAK ( Other Identifier: Eli Lilly and Company )
First Posted: February 23, 2012    Key Record Dates
Last Update Posted: June 27, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Evacetrapib
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents